Tredje AP fonden Acquires 72,876 Shares of Neurocrine Biosciences, Inc. $NBIX

Tredje AP fonden lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 626.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 84,503 shares of the company’s stock after purchasing an additional 72,876 shares during the period. Tredje AP fonden’s holdings in Neurocrine Biosciences were worth $11,985,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in NBIX. Royal Bank of Canada grew its holdings in shares of Neurocrine Biosciences by 36.7% during the 1st quarter. Royal Bank of Canada now owns 82,810 shares of the company’s stock valued at $9,158,000 after purchasing an additional 22,224 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Neurocrine Biosciences by 60.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,783 shares of the company’s stock valued at $1,647,000 after purchasing an additional 5,577 shares during the last quarter. NewEdge Advisors LLC grew its holdings in shares of Neurocrine Biosciences by 56.3% during the 1st quarter. NewEdge Advisors LLC now owns 7,630 shares of the company’s stock valued at $844,000 after purchasing an additional 2,747 shares during the last quarter. Empowered Funds LLC bought a new position in shares of Neurocrine Biosciences during the 1st quarter valued at $1,333,000. Finally, Geneos Wealth Management Inc. grew its holdings in shares of Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Activity

In other news, Director Leslie V. Norwalk sold 3,810 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $155.01, for a total value of $590,588.10. Following the completion of the sale, the director directly owned 2,429 shares of the company’s stock, valued at approximately $376,519.29. This trade represents a 61.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the completion of the sale, the director directly owned 34,480 shares of the company’s stock, valued at approximately $5,435,772. This represents a 30.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Neurocrine Biosciences from $177.00 to $185.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Wells Fargo & Company cut their price target on shares of Neurocrine Biosciences from $180.00 to $175.00 and set an “overweight” rating on the stock in a report on Friday, February 13th. HC Wainwright raised their price target on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Wedbush raised their price target on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Finally, Citigroup raised their target price on shares of Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $184.15.

Neurocrine Biosciences Trading Down 1.8%

NASDAQ:NBIX opened at $154.36 on Wednesday. The company has a 50-day moving average price of $135.12 and a 200-day moving average price of $138.57. Neurocrine Biosciences, Inc. has a 12 month low of $117.59 and a 12 month high of $162.39. The stock has a market cap of $15.52 billion, a price-to-earnings ratio of 23.78, a P/E/G ratio of 1.18 and a beta of 0.34.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.